Loading

Strategic Innovation: Building Smarter Pipelines for Challenging Targets

June 25, 2026
29AB
Type: Breakout Session
Focus Area: Translational Research
This session brings together leaders from early-to-late-stage biotech’s and the investment community to explore practical frameworks for transforming early-stage discoveries into development-ready therapeutic assets. Panelists will share concrete examples of early scientific work that has successfully evolved into new biotech companies, illustrating how thoughtful program design, early validation strategies, and milestone-driven execution can bridge the translational gap. The discussion will highlight how effective collaboration models and clear development roadmaps help reduce scientific, operational, and investment risk. Attendees will gain actionable insights into de-risking early-stage science, structuring productive partnerships, and aligning innovation with the expectations of industry and investors to accelerate the path from discovery to real-world therapeutic impact.

Subtopic

De-Risking Academic Science
Moderator
Elmar Nurmemmedov, ACA
CEO
Cellzyme Therapeutics
Speakers
Bradlee Heckmann, PhD
President & Chief Scientific Officer - Asha Therapeutics Life Science Partner - Arcadia Investment Partners
Asha Therapeutics Arcadia Investment Partners
Nam-Gu Her, PhD
CEO
Aimed Bio
Takahiro Nagayama, PhD
Head of Research Institute San Diego
Daiichi Sankyo, Inc.
Sonia Setayesh, PhD
Partner
Civilization Ventures
Alex Zhavoronkov, PhD
CEO & Founder
Insilico Medicine

white squarewhite

BIO DOUBLE HELIX SPONSORS

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

BIO HELIX SPONSORS

Loading